HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

Abstract
Current influenza vaccines elicit Abs to the hemagglutinin and neuraminidase envelope proteins. Due to antigenic drift, these vaccines must be reformulated annually to include the envelope proteins predicted to dominate in the following season. By contrast, vaccination with the conserved nucleoprotein (NP) elicits immunity against multiple serotypes (heterosubtypic immunity). NP vaccination is generally thought to convey protection primarily via CD8 effector mechanisms. However, significant titers of anti-NP Abs are also induced, yet the involvement of Abs in protection has largely been disregarded. To investigate how Ab responses might contribute to heterosubtypic immunity, we vaccinated C57BL/6 mice with soluble rNP. This approach induced high titers of NP-specific serum Ab, but only poorly detectable NP-specific T cell responses. Nevertheless, rNP immunization significantly reduced morbidity and viral titers after influenza challenge. Importantly, Ab-deficient mice were not protected by this vaccination strategy. Furthermore, rNP-immune serum could transfer protection to naive hosts in an Ab-dependent manner. Therefore, Ab to conserved, internal viral proteins, such as NP, provides an unexpected, yet important mechanism of protection against influenza. These results suggest that vaccines designed to elicit optimal heterosubtypic immunity to influenza should promote both Ab and T cell responses to conserved internal proteins.
AuthorsDamian M Carragher, Denise A Kaminski, Amy Moquin, Louise Hartson, Troy D Randall
JournalJournal of immunology (Baltimore, Md. : 1950) (J Immunol) Vol. 181 Issue 6 Pg. 4168-76 (Sep 15 2008) ISSN: 1550-6606 [Electronic] United States
PMID18768874 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Adjuvants, Immunologic
  • Antibodies, Viral
  • Influenza Vaccines
  • Lipopolysaccharides
  • NP protein, Influenza A virus
  • Nucleocapsid Proteins
  • RNA-Binding Proteins
  • Recombinant Proteins
  • Viral Core Proteins
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Animals
  • Antibodies, Viral (biosynthesis, physiology)
  • CD8-Positive T-Lymphocytes (immunology)
  • Immunity, Innate
  • Influenza A Virus, H3N8 Subtype (immunology)
  • Influenza Vaccines (administration & dosage, immunology)
  • Lipopolysaccharides (administration & dosage, immunology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Transgenic
  • Neutralization Tests
  • Nucleocapsid Proteins
  • Orthomyxoviridae Infections (immunology, mortality, prevention & control, virology)
  • RNA-Binding Proteins (administration & dosage, immunology, physiology)
  • Recombinant Proteins (administration & dosage, immunology)
  • Viral Core Proteins (administration & dosage, immunology, physiology)
  • Viral Load

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: